Ypsomed Holding AG
SIX:YPSN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
292
437
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Ypsomed Holding AG
Ypsomed Holding AG
Operating Income
Ypsomed Holding AG
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ypsomed Holding AG
SIX:YPSN
|
Operating Income
CHf86.8m
|
CAGR 3-Years
97%
|
CAGR 5-Years
44%
|
CAGR 10-Years
14%
|
|
|
Alcon AG
SIX:ALC
|
Operating Income
$1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Coltene Holding AG
SIX:CLTN
|
Operating Income
CHf18.2m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Medartis Holding AG
SIX:MED
|
Operating Income
CHf9.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
IVF Hartmann Holding AG
SIX:VBSN
|
Operating Income
CHf19.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
0%
|
|
Ypsomed Holding AG
Glance View
Nestled amid the pioneering spirit of the Swiss medical technology landscape, Ypsomed Holding AG emerges as a quintessential player, carving a niche in the diabetes care and injection systems domains. The company’s journey begins in the Ypsomed headquarters in Burgdorf, Switzerland, where innovation meets precision engineering. Ypsomed's focus largely revolves around its development, production, and distribution of self-injection devices and solutions. This Swiss dynamo engages in crafting state-of-the-art insulin pumps, pen injectors, and smart add-on devices that empower users with diabetes to manage their conditions effectively. It combines clinical expertise with intuitive design, ensuring that their diverse clientele—from patients to medical professionals—receive products that blend seamlessly into everyday life. Not resting on insulin delivery alone, Ypsomed also establishes itself in the world of contract manufacturing, catering to global pharmaceutical and biotech companies with their platform technology and customized solutions. Economically vibrant, Ypsomed’s revenue streams are woven intricately from an array of channels. A significant proportion stems from direct sales of its proprietary diabetes care products under their acclaimed mylife™ brand. Here, it garners a loyal customer base through innovations like the YpsoPump® system, effectively capitalizing on the growing demand for user-friendly diabetes management tools. Additionally, Ypsomed capitalizes on partnerships with major healthcare multinationals by providing contract manufacturing services and licensing technologies, expanding its global footprint while tapping into broader markets. As a strategic player, the company continuously invests in research and development to refine its offerings and maintain a competitive edge in the burgeoning medical device market. Through this dynamic blend of cutting-edge technology and strategic alliances, Ypsomed illustrates a sophisticated business model that not only sustains its profitability but furthers its mission to improve the lives of those in need of reliable, advanced diabetes care solutions.
See Also
What is Ypsomed Holding AG's Operating Income?
Operating Income
86.8m
CHF
Based on the financial report for Sep 30, 2024, Ypsomed Holding AG's Operating Income amounts to 86.8m CHF.
What is Ypsomed Holding AG's Operating Income growth rate?
Operating Income CAGR 10Y
14%
Over the last year, the Operating Income growth was 7%. The average annual Operating Income growth rates for Ypsomed Holding AG have been 97% over the past three years , 44% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet